Daptomycin

被引：77

作者：

Enoch, David A. ^{[1
]}

Bygott, Jeanine M. ^{[1
]}

Daly, Marie-Louise ^{[1
]}

Karas, J. Andreas ^{[1
]}

机构：

[1] Papworth Hosp, Hlth Protect Agcy, Clin Microbiol & Publ Hlth Lab, Cambridge CB3 8RE, England

来源：

JOURNAL OF INFECTION | 2007年 / 55卷 / 03期

关键词：

daptomycin; skin and soft tissue infection; bacteraemia and endocarditis; Gram positive infections;

D O I：

10.1016/j.jinf.2007.05.180

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

There has been a steady rise in the prevalence of resistant Gram-positive pathogens and concerns about the clinical effectiveness of glycopeptides in treating infections due to Staphylococcus aureus. Daptomycin is a novel lipopeptide antimicrobial agent with activity against Gram-positive organisms, including mufti-resistant strains. It is licensed in the USA and Europe for the treatment of complicated skin and soft tissue infections caused by Gram-positive organisms at a dose of 4 mg/kg once daily. It has also been licensed in the USA for the treatment of S. aureus bacteraemia and right-sided endocarditis at 6 mg/kg once daily. It is a safe and well-tolerated antibiotic, particularly at the current dosing regimen. Antimicrobial resistance, whilst being increasingly reported, still remains relatively rare. Further studies are required to determine the role of daptomycin for the treatment of osteomyelitis and septic arthritis, as well as its use in combination therapy. (c) 2007 The British Infection Society. Published by Elsevier Ltd. AR rights reserved.

引用

页码：205 / 213

页数：9

共 86 条

[1] Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus [J].

Antony, Suresh J. .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2006, 38 (04) :293-295

[2] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].

Arbeit, RD ;

Maki, D ;

Tally, FP ;

Campanaro, E ;

Eisenstein, BI .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681

[3] In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci:: first results from Turkey [J].

Arslan, H ;

Azap, ÖK ;

Ergin, F ;

Karaman, SÖ ;

Oruç, E .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (06) :642-643

[4] In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers [J].

Barry, AL ;

Fuchs, PC ;

Brown, SD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1919-1922

[5] Daptomycin-rifampin for a recurrent MRSA joint infection unresponsive to vancomycin-based therapy [J].

Burns, CA .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2006, 38 (02) :133-136

[6] LIPOTEICHOIC ACID AS A NEW TARGET FOR ACTIVITY OF ANTIBIOTICS - MODE OF ACTION OF DAPTOMYCIN (LY146032) [J].

CANEPARI, P ;

BOARETTI, M ;

LLEO, MD ;

SATTA, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (06) :1220-1226

[7] Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens [J].

Carpenter, CF ;

Chambers, HF .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :994-1000

[8]

Cilli F, 2006, J CHEMOTHERAPY, V18, P27

[9] Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia:: A meta-analysis [J].

Cosgrove, SE ;

Sakoulas, G ;

Perencevich, EN ;

Schwaber, MJ ;

Karchmer, AW ;

Carmeli, Y .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) :53-59

[10] The impact of methicillin-resistance in Staphylococcus aureus bacteremia on patient outcomes:: Mortality, length of stay, and hospital charges [J].

Cosgrove, SE ;

Qi, YL ;

Kaye, KS ;

Harbarth, S ;

Karchmer, AW ;

Carmeli, Y .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2005, 26 (02) :166-174

← 1 2 3 4 5 6 7 8 9 →